Fda approves intra-cellular therapies' novel antipsychotic, caplyta for the treatment of schizophrenia in adults

Fda approves intra-cellular therapies’ novel antipsychotic, caplyta® (lumateperone) for the treatment of schizophrenia in adults.intra-cellular therapies inc - expects to initiate commercial launch of caplyta in late q1 2020..

ITCI Ratings Summary

ITCI Quant Ranking